Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$376.04 +1.2%	$351.28	$269.77 ▼ $391.29	$202.95B	0.41	2.16 million shs	2.49 million shs
BIIB Biogen	$202.19 +0.8%	$199.78	$124.56 ▼ $219.72	$29.85B	0.16	1.44 million shs	596,261 shs
GILD Gilead Sciences	$129.31 -1.2%	$129.55	$108.46 ▼ $157.29	$160.55B	0.32	7.12 million shs	5.53 million shs
MRNA Moderna	$54.07 -5.2%	$58.52	$22.28 ▼ $85.60	$21.45B	0.94	7.48 million shs	4.42 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+2.66%	+6.58%	+9.14%	+21.61%
BIIB Biogen	0.00%	-1.84%	+0.11%	+9.66%	+54.37%
GILD Gilead Sciences	0.00%	-3.70%	+4.42%	-0.84%	+13.87%
MRNA Moderna	0.00%	-12.54%	-9.51%	+6.58%	+55.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$376.04 +1.2%	$351.28	$269.77 ▼ $391.29	$202.95B	0.41	2.16 million shs	2.49 million shs
BIIB Biogen	$202.19 +0.8%	$199.78	$124.56 ▼ $219.72	$29.85B	0.16	1.44 million shs	596,261 shs
GILD Gilead Sciences	$129.31 -1.2%	$129.55	$108.46 ▼ $157.29	$160.55B	0.32	7.12 million shs	5.53 million shs
MRNA Moderna	$54.07 -5.2%	$58.52	$22.28 ▼ $85.60	$21.45B	0.94	7.48 million shs	4.42 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+2.66%	+6.58%	+9.14%	+21.61%
BIIB Biogen	0.00%	-1.84%	+0.11%	+9.66%	+54.37%
GILD Gilead Sciences	0.00%	-3.70%	+4.42%	-0.84%	+13.87%
MRNA Moderna	0.00%	-12.54%	-9.51%	+6.58%	+55.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.43	Hold	$356.62	-5.17% Downside
BIIB Biogen	2.53	Moderate Buy	$220.57	9.09% Upside
GILD Gilead Sciences	2.86	Moderate Buy	$158.33	22.44% Upside
MRNA Moderna	1.82	Reduce	$40.00	-26.02% Downside

Current Analyst Ratings Breakdown

Latest GILD, BIIB, AMGN, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	BIIB Biogen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $280.00
7/21/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$49.00 ➝ $67.00
7/21/2026	BIIB Biogen	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$217.00 ➝ $215.00
7/21/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$146.00 ➝ $127.00
7/20/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$25.00
7/15/2026	AMGN Amgen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/14/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/13/2026	BIIB Biogen	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$400.00 ➝ $420.00
7/13/2026	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$201.00
7/13/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$340.00 ➝ $343.00

(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	5.52	$33.82 per share	11.12	$16.08 per share	23.39
BIIB Biogen	$9.89B	3.02	$22.64 per share	8.93	$124.45 per share	1.62
GILD Gilead Sciences	$29.44B	5.45	$10.47 per share	12.35	$18.23 per share	7.09
MRNA Moderna	$1.94B	11.04	N/A	N/A	$22.14 per share	2.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	26.17	15.76	3.80	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	21.69	12.23	N/A	13.81%	12.83%	8.01%	7/29/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	17.62	13.29	N/A	30.99%	48.19%	18.28%	8/4/2026 (Confirmed)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)

Latest GILD, BIIB, AMGN, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GILD Gilead Sciences	-$7.2478	N/A	N/A	N/A	$7.39 billion	N/A
8/4/2026	Q2 2026	AMGN Amgen	$5.62	N/A	N/A	N/A	$9.43 billion	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.00	N/A	N/A	N/A	$103.07 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$3.02	N/A	N/A	N/A	$2.46 billion	N/A
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.68%	+8.27%	70.15%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.54%	+3.04%	44.69%	10 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest GILD, BIIB, AMGN, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.64%	6/15/2026	6/15/2026	6/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
BIIB Biogen	0.34	3.06	2.41
GILD Gilead Sciences	0.89	1.97	1.77
MRNA Moderna	0.08	2.41	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BIIB Biogen	0.25%
GILD Gilead Sciences	0.30%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.71 million	535.12 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable

GILD, BIIB, AMGN, and MRNA Headlines

Recent News About These Companies

Barclays Reaffirms Their Hold Rating on Moderna (MRNA)

July 25 at 12:46 AM | theglobeandmail.com

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions

July 25 at 9:44 AM | stocktwits.comS

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

July 24 at 1:43 PM | finance.yahoo.com

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

July 24 at 11:01 AM | zacks.com

First Trust Advisors LP Raises Stock Position in Moderna, Inc. $MRNA

July 24 at 4:00 AM | marketbeat.com

Moderna (MRNA) to Announce Quarterly Earnings on Friday

July 24 at 1:26 AM | americanbankingnews.com

Moderna (MRNA) Projected to Post Earnings on Friday

July 24 at 1:25 AM | marketbeat.com

Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?

July 22, 2026 | finance.yahoo.com

Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA

July 22, 2026 | marketbeat.com

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

July 22, 2026 | marketbeat.com

Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA

July 22, 2026 | marketbeat.com

Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift

July 21, 2026 | finance.yahoo.com

Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp

July 21, 2026 | marketbeat.com

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

July 20, 2026 | finance.yahoo.com

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

July 20, 2026 | zacks.com

Moderna says CureVac broke agreement by suing over COVID vaccine patents

July 20, 2026 | reuters.com

D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA

July 20, 2026 | marketbeat.com

MRNA Advances Cancer Pipeline With New Immunotherapy Study

July 17, 2026 | finance.yahoo.com

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

July 17, 2026 | finance.yahoo.com

MRNA Advances Cancer Pipeline With New Immunotherapy Study

July 17, 2026 | zacks.com

A personalized melanoma vaccine cut recurrence risk by 49% in a Moderna and Merck trial

July 17, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GILD, BIIB, AMGN, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$376.04 +4.54 (+1.22%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$374.50 -1.54 (-0.41%)

As of 07/24/2026 07:34 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$202.19 +1.57 (+0.78%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$201.20 -1.00 (-0.49%)

As of 07/24/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$129.31 -1.55 (-1.18%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$130.46 +1.15 (+0.89%)

As of 07/24/2026 07:34 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$54.07 -2.95 (-5.17%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$54.14 +0.07 (+0.13%)

As of 07/24/2026 07:34 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, BIIB, AMGN, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, BIIB, AMGN, and MRNA Earnings

Compare Dividends

Latest GILD, BIIB, AMGN, and MRNA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, BIIB, AMGN, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, BIIB, AMGN, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Gilead Sciences NASDAQ:GILD

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools